Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
1059 participants
INTERVENTIONAL
2025-09-30
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The World Health Organization (WHO) recommends that all pregnant women receive at least one ultrasound scan before 24 weeks of gestation, yet nearly two-thirds of women worldwide-especially in LMICs-lack access to this service. Barriers include high costs of ultrasound machines, limited technical expertise, and shortages of skilled sonographers in rural primary care.
Artificial Intelligence-driven Point-of-Care Ultrasound (AI-POCUS) represents a promising innovation to expand prenatal imaging in resource-constrained settings by equipping frontline health workers with AI-supported diagnostic capabilities. This study, conducted under the Tsinghua University BRIGHT (Bringing Research to Impact for Global Health at Tsinghua) program, will evaluate the clinical effectiveness, feasibility, cost, and scalability of AI-POCUS in rural Ethiopia. A three-arm cluster randomized controlled trial will compare two AI-enabled ultrasound technologies-BabyChecker (Netherlands) and a China-developed AI-POCUS device-against standard antenatal care without ultrasound. Findings will generate robust clinical and policy-relevant evidence to guide the sustainable implementation of AI-enabled maternal health interventions in sub-Saharan Africa.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reliability of Simple Sonographic Findings Acquired With Hand-held Apparatuses to Inform Obstetric Diagnosis
NCT03856307
Improving Intrapartum Care for Saving Life at Birth in Ethiopia Through PartoMa Approach
NCT06273007
Automated Analysis Algorithms in Second Trimester Obstetric Ultrasound
NCT04441866
WHO Fetal Growth Charts
NCT03755024
Developing and Testing AI Models for Fetal Biometry and Amniotic Volume Assessment in Fetal Ultrasound Scans.
NCT05059093
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ultrasound imaging is a cornerstone of modern antenatal care. The WHO recommends at least one ultrasound before 24 weeks' gestation to assess gestational age, detect multiple pregnancies, identify fetal anomalies, and diagnose high-risk conditions such as preeclampsia, placenta previa, or growth restriction. However, nearly two-thirds of pregnant women worldwide still lack access to this basic diagnostic tool. In low-resource environments, the barriers include limited infrastructure, high equipment costs, technical complexity, and the scarcity of trained professionals capable of performing and interpreting scans. As a result, potentially preventable maternal and neonatal deaths remain common.
Artificial Intelligence-driven Point-of-Care Ultrasound (AI-POCUS) introduces a transformative opportunity to address these gaps. POCUS devices embedded with AI algorithms can guide non-specialist health workers in image acquisition and interpretation, reducing reliance on highly trained personnel and lowering barriers to integration within primary care. Such innovations may strengthen early detection of pregnancy complications, enable timely referral to higher-level care, and ultimately improve maternal and neonatal survival.
This study is embedded within the Bringing Research to Impact for Global Health at Tsinghua (BRIGHT) initiative. It will use a three-arm cluster randomized controlled trial (C-RCT) design to evaluate and compare: (1) BabyChecker, a portable AI-enabled ultrasound developed in the Netherlands, (2) A China-developed AI-POCUS device, and (3) Standard antenatal care (ANC) without ultrasound, reflecting current practice in many rural Ethiopian communities.
The study population will include pregnant women receiving antenatal care in rural Ethiopia, as well as primary health care providers delivering these services. Data will be collected at both the patient and facility level to capture maternal and neonatal health outcomes, health service utilization, and system-level performance indicators.
Evaluation will follow a multi-dimensional framework, addressing:
1. Clinical effectiveness: improved detection of high-risk pregnancies, reduced maternal and neonatal complications, and mortality.
2. Implementation feasibility and acceptability: user experience among health workers and pregnant women, integration into routine workflows, and perceived trust in AI-assisted care.
3. Economic evaluation: cost and cost-effectiveness of AI-POCUS compared to standard ANC, including resource utilization, referral patterns, and potential savings from earlier detection.
4. Scalability and policy relevance: analysis of barriers and enablers for broader adoption in Ethiopia and similar LMIC contexts, with direct input from policymakers and health system stakeholders.
The study aims to provide rigorous clinical evidence and practical implementation guidance on how AI-POCUS technologies can be sustainably scaled in resource-constrained settings. Findings are expected to inform national health policies, guide investment decisions, and offer a replicable model for expanding maternal health technologies across sub-Saharan Africa and other LMICs.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
A total of 1,059 pregnant women will be recruited, with 353 participants per study arm. Interventions will be implemented at the cluster level, while outcomes - including maternal and neonatal health indicators - will be assessed at the individual participant level. This design allows for the evaluation of the effectiveness and feasibility of AI-POCUS interventions while accounting for intra-cluster correlation and contextual variability across health centers.
SCREENING
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard Care Control
Participants in this arm will receive routine antenatal care (ANC) according to Ethiopian national guidelines, without the use of AI-POCUS devices. All examinations, screenings, and referrals will be conducted through standard clinical practice. This group serves as the baseline comparator for evaluating the added impact of AI-POCUS technology.
No interventions assigned to this group
BabyChecker (Delft Imaging, Netherlands)
Health centers in this arm will be equipped with the BabyChecker system developed by Delft Imaging (Netherlands). The portable device integrates fetal position, amniotic fluid volume, and biparietal diameter measurements, and provides diagnostic suggestions and risk alerts. After brief training, primary healthcare workers will independently perform antenatal examinations, screen for obstetric complications, and make referral decisions.
AI-POCUS (BabyChecker, Delft Imaging)
A portable AI-driven ultrasound system developed by Delft Imaging (Netherlands). The device integrates fetal position, amniotic fluid volume, and biparietal diameter measurements, with built-in diagnostic suggestions and risk alerts. Primary healthcare workers, after brief training, use it for antenatal screening, complication detection, and referral decision-making.
AI-POCUS (Edan, China)
This arm will use the AI-POCUS device developed by Edan (China), designed to analyze blind ultrasound sweeps and automatically extract fetal diagnostic parameters. The system supports the early detection of maternal and fetal risks and assists in clinical decision-making.
AI-POCUS (Edan, China)
An AI-POCUS device developed by Edan (China), capable of analyzing blind ultrasound sweeps to extract fetal diagnostic parameters and assist in early risk identification. It supports clinical decision-making for antenatal care.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AI-POCUS (BabyChecker, Delft Imaging)
A portable AI-driven ultrasound system developed by Delft Imaging (Netherlands). The device integrates fetal position, amniotic fluid volume, and biparietal diameter measurements, with built-in diagnostic suggestions and risk alerts. Primary healthcare workers, after brief training, use it for antenatal screening, complication detection, and referral decision-making.
AI-POCUS (Edan, China)
An AI-POCUS device developed by Edan (China), capable of analyzing blind ultrasound sweeps to extract fetal diagnostic parameters and assist in early risk identification. It supports clinical decision-making for antenatal care.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Gestational age less than 24 weeks at the first ANC visit;
3. No history of severe pregnancy complications (e.g., placenta previa, preeclampsia, etc.);
4. Signed informed consent and agreed to participate in the study.
Exclusion Criteria
2. Failure to complete antenatal care within the specified timeframe;
3. Incomplete or unavailable records of antenatal care and delivery.
15 Years
49 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Debre Berhan University
OTHER
Tsinghua University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yuxuan LI
Doctoral Candidate
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kun TANG, Associate Professor
Role: STUDY_CHAIR
Tsinghua University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hakim Gizaw Hospital
Debre Berhan, Amhara, Ethiopia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BRIGHT (202430045)
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
PROJECT #: BRIGHT (202430045)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.